The ruthenium based anti-tumour drug NKP-1339 has been developed by the Bernhard Keppler group of the Institute of Inorganic Chemistry in cooperation with the Medical University of Vienna. The first clinical phase I study was recently concluded and has shown promising results.
- Neuer Krebswirkstoff erfolgreich getestet (uni:view Magazin 29.8.2012, in German)
